Research Analysts Set Expectations for FDMT FY2026 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of 4D Molecular Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.86) for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02).

Other analysts have also issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, May 24th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Bank of America lowered their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. Royal Bank of Canada cut their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Finally, Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.56.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $4.47 on Wednesday. The company has a market cap of $207.07 million, a PE ratio of -1.57 and a beta of 2.84. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The stock’s 50 day simple moving average is $3.34 and its two-hundred day simple moving average is $4.58.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC raised its stake in shares of 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after acquiring an additional 367,317 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the 1st quarter worth $39,000. Millennium Management LLC raised its position in 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares in the last quarter. BVF Inc. IL lifted its holdings in shares of 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock worth $14,733,000 after buying an additional 1,890,647 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth $46,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.